Internal Medicine, Critical Care Medicine · Kissimmee, FL
NPI
1124025309
Since 2005
Specialty
Internal Medicine, Critical Care Medicine
Code 207RC0200X
Group practices
3
Medicare group memberships
Hospitals
4
Hospital affiliations
3480 Polynesian Isle Blvd
Kissimmee, FL, 34746
Phone (407) 507-2615
Groups this clinician bills Medicare through
Medicare paid, 2024
$853K
23,221 services
Medicare patients, 2024
1,149
Average age 74
Drug cost, 2024
$5.5M
4,605 prescriptions
Company payments, 2025
$81K
From 31 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Fortune O Alabi was code J0517 (injection, benralizumab, 1 mg), 2,073 times for 16 patients. In total Fortune O Alabi billed 23,221 services in 60 codes, and Medicare paid $853K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-04-01.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0517 Injection, benralizumab, 1 mg | Office | 2,073 | 16 | $131.07 | $272K |
| 99213 Office E&M - Established | Office | 600 | 416 | $63.86 | $38K |
| 99214 Office E&M - Established | Office | 549 | 339 | $92.36 | $51K |
| 94010 Pulmonary Function Testing | Office | 522 | 428 | $19.55 | $10K |
| 94726 Pulmonary Function Testing | Office | 477 | 403 | $40.64 | $19K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 474 | 343 | $12.40 | $5,877 |
| 94729 Pulmonary Function Testing | Office | 459 | 386 | $41.29 | $19K |
| 99232 Hospital E&M - Subsequent | Facility | 339 | 192 | $61.26 | $21K |
| 99233 Hospital E&M - Subsequent | Facility | 312 | 182 | $92.48 | $29K |
| 96372 Injection Administration | Office | 196 | 34 | $10.51 | $2,060 |
| 71250 CT/CTA - Chest | Office | 136 | 121 | $96.30 | $13K |
| 99204 Office E&M - New | Office | 107 | 107 | $120.11 | $13K |
| 99291 Critical Care E&M | Facility | 81 | 49 | $167.24 | $14K |
| 71046 X-ray - Chest | Office | 72 | 64 | $24.28 | $1,748 |
| 99205 Office E&M - New | Office | 68 | 68 | $157.76 | $11K |
By year: 2022 $588K for 13,436 services; 2023 $732K for 17,624 services; 2024 $853K for 23,221 services.
Medicare prescription drug claims, 2024
In 2024, the drug Fortune O Alabi prescribed most often to Medicare patients was Trelegy Ellipta (Fluticasone/Umeclidin/Vilanter), with 711 prescriptions and refills. In total Fortune O Alabi wrote 4,605 Medicare prescriptions that cost $5.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | 711 | 995 | 170 | $622K |
| Albuterol Sulfate Hfa Albuterol Sulfate | 432 | 508 | 186 | $12K |
| Montelukast Sodium Generic | 273 | 613 | 85 | $3,048 |
| Prednisone Generic | 242 | 300 | 119 | $910 |
| Breo Ellipta Fluticasone/Vilanterol | 212 | 296 | 54 | $117K |
| Symbicort Budesonide/Formoterol Fumarate | 208 | 303 | 67 | $69K |
| Breztri Aerosphere Budesonide/Glycopyr/Formoterol | 143 | 241 | 47 | $143K |
| Fluticasone-Salmeterol Fluticasone Propion/Salmeterol | 136 | 176 | 51 | $21K |
| Azithromycin Generic | 103 | 142 | 35 | $4,301 |
| Anoro Ellipta Umeclidinium Brm/Vilanterol Tr | 93 | 111 | 23 | $49K |
| Spiriva Respimat Tiotropium Bromide | 88 | 150 | 29 | $77K |
| Wixela Inhub Fluticasone Propion/Salmeterol | 86 | 122 | 31 | $9,761 |
| Breyna Budesonide/Formoterol Fumarate | 85 | 108 | 27 | $15K |
| Levocetirizine Dihydrochloride Generic | 78 | 166 | 27 | $1,380 |
| Ofev Nintedanib Esylate | 75 | 75 | 16 | $971K |
Brand drugs: 2,568 claims; generic drugs: 2,037 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Fortune O Alabi $81K ($81K in general payments such as food, travel and fees) from 31 companies. The largest payer was ANI Pharmaceuticals, Inc. with $28K.
| Company | Payments | Amount |
|---|---|---|
| ANI Pharmaceuticals, Inc. ANIP | 29 | $28K |
| Mallinckrodt Hospital Products Inc. | 19 | $19K |
| AstraZeneca Pharmaceuticals LP AZN | 39 | $10K |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 33 | $9,270 |
| Verona Pharma, Inc. VRNA | 18 | $5,783 |
| Genzyme Corporation SNY | 11 | $4,804 |
| United Therapeutics Corporation UTHR | 11 | $766 |
| Actelion Pharmaceuticals US, Inc. JNJ | 17 | $731 |
| Insmed, Inc. INSM | 17 | $424 |
| Regeneron Healthcare Solutions, Inc. REGN | 20 | $355 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.